Intrauterine Growth Restriction Clinical Trial
Intrauterine growth restriction is a common and complex obstetric problem. Intrauterine
growth restriction is noted to affect approximately 10-15 % of pregnant women. Intrauterine
growth restriction is diagnosed antenatal; however, some of these fetuses, especially if
unscreened during pregnancy, may be detected only in the neonatal period. It is very
important for obstetricians and perinatologists to identify growth restricted fetuses,
because this fetal condition is associated with significant perinatal morbidity and
mortality.
Omega 3 is composed of polyunsaturated fatty acids with a double bond at the third carbon
atom from the end of the carbon chain. The fatty acids have two ends, the carboxylic acid
end, which is considered the beginning of the chain, thus "alpha", and the methyl end, which
is considered the "tail" of the chain, thus "omega." Omega3 improve fetal wellbeing by two
mechanisms: Firstly, maternal and docosahexaenoic acid supplementation during pregnancy and
lactation normalizes intrauterine growth restriction induced changes in adipose deposition
and visceral PPARĪ³ expression. Secondly, maternal docosahexaenoic acid supplementation
increases serum adiponectin, as well as adipose expression of adiponectin and adiponectin
receptors. Novel findings suggest that maternal docosahexaenoic acid supplementation
normalize adipose dysfunction and promote adiponectin-induced improvements in metabolic
function in intrauterine growth restriction
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04506970 -
Predicting Placental Pathologies by Ultrasound Imaging
|
||
| Recruiting |
NCT03866863 -
Intra Uterine Growth Restriction
|
||
| Recruiting |
NCT03662178 -
Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
|
||
| Not yet recruiting |
NCT05720169 -
Fetal, Obstetrics and Reproduction Genomics
|
||
| Completed |
NCT04633551 -
Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes
|
N/A | |
| Recruiting |
NCT05500989 -
PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
|
||
| Recruiting |
NCT04141189 -
Comparison of Follow-up Protocols in Terms of Fetal, Neonatal and Maternal Results in Intrauterine Growth Retardation
|
N/A | |
| Completed |
NCT03726697 -
Effect of Tahneek on Hypoglycemia in Newborn Infants
|
N/A | |
| Not yet recruiting |
NCT06226051 -
Growing Little PEAPODS Study
|
||
| Recruiting |
NCT03398629 -
Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies
|
||
| Recruiting |
NCT02473991 -
Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight
|
N/A | |
| Recruiting |
NCT04766866 -
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
|
N/A | |
| Terminated |
NCT04047966 -
Study of the Fetal and Maternal Microbiota in Preganant Women With Fetal Defect Growth
|
||
| Not yet recruiting |
NCT03865628 -
Ultrasound Evaluation of Fetal Hemodynamics and Perinatal Complications
|
||
| Completed |
NCT05328453 -
Sonographic 3D Measurement of Fetal Thymus May be Used to Predict the Small Baby in Pregnancy.
|
||
| Completed |
NCT05800938 -
The Effect of Oral Isosorbide Mononitrate Therapy on Umbilical Artery Doppler Resistance Index in Pregnancies With Intrauterine Growth Restriction: Prospective Randomized Control Trial
|
Phase 4 | |
| Recruiting |
NCT02807324 -
Women Specific Cardiac Recovery After Preeclampsia
|
||
| Recruiting |
NCT02515292 -
Evaluation of Infants With Intrauterine Growth Restriction
|
N/A | |
| Active, not recruiting |
NCT01942525 -
Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
|
N/A | |
| Withdrawn |
NCT04557475 -
Transplacental Aspirin Therapy for Early Onset Fetal Growth Restriction
|
Phase 3 |